ReviewDrug testing and analysis
Current knowledge on cannabinoids in oral fluid.
Review in Drug testing and analysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Pharmacological evidence of medicinal cannabis in oncology: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Pooled it
- Detection of ΔDrug testing and analysis · 2024Trial
- Orally administered cannabidiol does not produce false-positive tests for ΔDrug testing and analysis · 2022Trial
- Detection of ΔDrug testing and analysis · 2019Trial
- Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials.Drug and alcohol dependence · 2018Trial
- Enhancing Methods for Research on Cannabis: A Workshop Report.Journal of cannabis research · 2025Review
- Quantitative analysis of ΔAnalytical and bioanalytical chemistry · 2025Article
- Article
- Detection of Cannabinoids in Oral Fluid Specimens as the Preferred Biological Matrix for a Point-of-Care Biosensor Diagnostic Device.Biosensors · 2024Review
- Development of Mobile Contingency Management for Cannabis Use Reduction.Behavior therapy · 2024Article
- Comparing presumptive with direct-to-definitive drug testing in oral fluid vs. urine for a U.S. national sample of individuals misusing drugs.Drug and alcohol dependence · 2023Article
- Simple Method for the Determination of THC and THC-COOH in Human Postmortem Blood Samples by Gas Chromatography-Mass Spectrometry.Molecules (Basel, Switzerland) · 2023Article
- Machine Learning-Based Quantification of (-)-ACS omega · 2022Article
- Review
- Bridging Disciplines: Applications of Forensic Science and Industrial Hemp.Frontiers in microbiology · 2022Review
- Detection of carbamazepine in saliva based on surface-enhanced Raman spectroscopy.Biomedical optics express · 2021Article
- A rapid assay provides on-site quantification of tetrahydrocannabinol in oral fluid.Science translational medicine · 2021Article
- Study of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) extraction FROM dried oral fluid spots (DOFS) and LC-MS/MS detection.Journal of cannabis research · 2021Article
- Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges.Current addiction reports · 2019Article
- Synthetic Cannabinoid Receptor Agonists Detection Using Fluorescence Spectral Fingerprinting.Analytical chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Oral fluid (OF) is a new biological matrix for clinical and forensic drug testing, offering non-invasive and directly observable sample collection reducing adulteration potential, ease of multiple sample collections, lower biohazard risk during collection, recent exposure identification, and stronger correlation with blood than urine concentrations. Because cannabinoids are usually the most prevalent analytes in illicit drug testing, application of OF drug testing requires sufficient scientific data to support sensitive and specific OF cannabinoid detection. This review presents current knowledge of OF cannabinoids, evaluating pharmacokinetic properties, detection windows, and correlation with other biological matrices and impairment from field applications and controlled drug administration studies. In addition, onsite screening technologies, confirmatory analytical methods, drug stability, and effects of sample collection procedure, adulterants, and passive environmental exposure are reviewed. Delta-9-tetrahydrocannabinol OF concentrations could be >1000 µg/L shortly after smoking, whereas minor cannabinoids are detected at 10-fold and metabolites at 1000-fold lower concentrations. OF research over the past decade demonstrated that appropriate interpretation of test results requires a comprehensive understanding of distinct elimination profiles and detection windows for different cannabinoids, which are influenced by administration route, dose, and drug use history. Thus, each drug testing program should establish cut-off criteria, collection/analysis procedures, and storage conditions tailored to its purposes. Building a scientific basis for OF testing is ongoing, with continuing OF cannabinoids research on passive environmental exposure, drug use history, donor physiological conditions, and oral cavity metabolism needed to better understand mechanisms of cannabinoid OF disposition and expand OF drug testing applicability. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.